中国计划生育和妇产科
中國計劃生育和婦產科
중국계화생육화부산과
CHINESE JOURNAL OF FAMILY PLANNING & GYNECOTOKOLOGY
2015年
7期
18-21
,共4页
垂体降调节%促性腺激素释放激素激动剂长方案%降调节剂量%妊娠结局
垂體降調節%促性腺激素釋放激素激動劑長方案%降調節劑量%妊娠結跼
수체강조절%촉성선격소석방격소격동제장방안%강조절제량%임신결국
pituitary down-regulation%agonist of the gonadotropin releasing hormone%dose of pituitary down -regulation%pregnancy outcomes
目的:研究促性腺激素释放激素激动剂( gonadotrophin releasing hormone agonist,GnRH-a)长方案中垂体降调节剂量与体外受精( in-vitro fertilization, IVF)/卵胞浆内单精子注射( intracytoplasmic sperm injection, ICSI)结局的相关性。方法选取2010年9月至2012年12月在上海市同济医院生殖中心行IVF/ICSI治疗并进行移植的129个周期的临床资料,根据降调节剂量分为A组和B组。 A组62个周期,采用达菲林1.25 mg(1/3剂量)降调节;B组67个周期,采用达菲林0.94 mg(1/4剂量)降调节。分析两种不同剂量降调节与 IVF/ICSI 妊娠结局的关系。结果 A 组促性腺激素( gonadotropoin, Gn )量[(2530.04±782.04)IU]大于B组[(2231.03±759.79)IU](P<0.05);而两组Gn使用时间比较差异无统计学意义(P>0.05);两组患者的获卵数、成熟卵细胞个数、卵子受精数、卵子受精率、卵裂个数、卵裂率、优质胚胎数、优胚率比较差异均无统计学意义( P>0.05);两组患者的胚胎移植个数、胚胎种植数、胚胎种植率比较差异无统计学意义( P >0.05);两组患者临床妊娠率、早期流产率、卵巢过度刺激综合征( ovarian hyper -stimulation syndrome, OHSS)发生率及异位妊娠发生率比较差异无统计学意义(P>0.05)。结论长效达菲林1.25 mg相对于0.94 mg降调节导致Gn的剂量增加,但Gn使用时间并不延长,因此,对于垂体降调节GnRH-a的用量可根据患者的基础情况来制定方案。
目的:研究促性腺激素釋放激素激動劑( gonadotrophin releasing hormone agonist,GnRH-a)長方案中垂體降調節劑量與體外受精( in-vitro fertilization, IVF)/卵胞漿內單精子註射( intracytoplasmic sperm injection, ICSI)結跼的相關性。方法選取2010年9月至2012年12月在上海市同濟醫院生殖中心行IVF/ICSI治療併進行移植的129箇週期的臨床資料,根據降調節劑量分為A組和B組。 A組62箇週期,採用達菲林1.25 mg(1/3劑量)降調節;B組67箇週期,採用達菲林0.94 mg(1/4劑量)降調節。分析兩種不同劑量降調節與 IVF/ICSI 妊娠結跼的關繫。結果 A 組促性腺激素( gonadotropoin, Gn )量[(2530.04±782.04)IU]大于B組[(2231.03±759.79)IU](P<0.05);而兩組Gn使用時間比較差異無統計學意義(P>0.05);兩組患者的穫卵數、成熟卵細胞箇數、卵子受精數、卵子受精率、卵裂箇數、卵裂率、優質胚胎數、優胚率比較差異均無統計學意義( P>0.05);兩組患者的胚胎移植箇數、胚胎種植數、胚胎種植率比較差異無統計學意義( P >0.05);兩組患者臨床妊娠率、早期流產率、卵巢過度刺激綜閤徵( ovarian hyper -stimulation syndrome, OHSS)髮生率及異位妊娠髮生率比較差異無統計學意義(P>0.05)。結論長效達菲林1.25 mg相對于0.94 mg降調節導緻Gn的劑量增加,但Gn使用時間併不延長,因此,對于垂體降調節GnRH-a的用量可根據患者的基礎情況來製定方案。
목적:연구촉성선격소석방격소격동제( gonadotrophin releasing hormone agonist,GnRH-a)장방안중수체강조절제량여체외수정( in-vitro fertilization, IVF)/란포장내단정자주사( intracytoplasmic sperm injection, ICSI)결국적상관성。방법선취2010년9월지2012년12월재상해시동제의원생식중심행IVF/ICSI치료병진행이식적129개주기적림상자료,근거강조절제량분위A조화B조。 A조62개주기,채용체비림1.25 mg(1/3제량)강조절;B조67개주기,채용체비림0.94 mg(1/4제량)강조절。분석량충불동제량강조절여 IVF/ICSI 임신결국적관계。결과 A 조촉성선격소( gonadotropoin, Gn )량[(2530.04±782.04)IU]대우B조[(2231.03±759.79)IU](P<0.05);이량조Gn사용시간비교차이무통계학의의(P>0.05);량조환자적획란수、성숙란세포개수、란자수정수、란자수정솔、란렬개수、란렬솔、우질배태수、우배솔비교차이균무통계학의의( P>0.05);량조환자적배태이식개수、배태충식수、배태충식솔비교차이무통계학의의( P >0.05);량조환자림상임신솔、조기유산솔、란소과도자격종합정( ovarian hyper -stimulation syndrome, OHSS)발생솔급이위임신발생솔비교차이무통계학의의(P>0.05)。결론장효체비림1.25 mg상대우0.94 mg강조절도치Gn적제량증가,단Gn사용시간병불연장,인차,대우수체강조절GnRH-a적용량가근거환자적기출정황래제정방안。
Objective To study the correlation of dose of pituitary down-regulation and in-vitro fertilization/intracytoplasmic sperm injection( IVF/ICSI) outcomes in gonadotropin releasing hormone agonist ( GnRH-a) long protocol.Methods Clinical data 129 cycle with IVF/ICSI in Shanghai Tongji Hospital Reproductive Center from Sept 2010 to Dec 2012 were selected, All cases were divided into dose group A and dose group B according to the dose of down-regulation.Dose group A:62 cycles with Diphereline 1.25 mg dose (1/3) for down-regulation.Dose group B:67 cycles by Diphereline 0.94 mg (1/4 doses) for down-regulation.To Analyze the relationship between the two different doses and IVF/ICSI pregnancy outcomes.Results The dose of Gn in the dose group A was[ (2 530.04 +782.04) IU] significantly higher than that in the dose B group [(2 231.03 +759.79) IU] (P<0.05).The time of Gn between two groups had no statistically significant difference ( P >0.05 ) .The oocytes, the number of mature egg cell number, egg number, egg fertilization rate, cleavage, cleavage rate, high quality embryo number, good quality embryo rate of two groups, had no statistically significant difference (P>0.05);The patients with embryo transfer number, embryo implantation, embryo implantation rate of two groups had no statistically significant difference (P>0.05); Patients with clinical pregnancy rate, abortion rate and OHSS rate and ectopic pregnancy rate of two groups had no statistically significant difference (P>0.05).Conclusion 1.25 mg Diphereline for down-regulation increases the dose of GN compared to 0.94 mg Diphereline, but the time of GN do not extend. Therefore, The dose of GnRH-a for pituitary down-regulation may change according to the basic condition of the patients.